13649-88-2

Usage

Uses

Used in Pharmaceutical Industry:
Deflazacort is used as an intermediate for the production of various corticosteroid medications. It is particularly useful in the treatment of various inflammatory and autoimmune conditions, such as rheumatoid arthritis, lupus, and asthma. As a corticosteroid, it works by reducing inflammation, suppressing the immune system, and alleviating symptoms associated with these conditions.
Additionally, Deflazacort may be used in the development of new pharmaceutical compounds that target specific conditions or diseases. Its role as an intermediate allows for the creation of more effective and targeted medications, potentially improving patient outcomes and quality of life.

InChI:InChI=1/C23H29NO4/c1-12(25)23-19(28-13(2)24-23)10-17-16-6-5-14-9-15(26)7-8-21(14,3)20(16)18(27)11-22(17,23)4/h7-9,16-20,27H,5-6,10-11H2,1-4H3/t16-,17-,18-,19+,20+,21-,22-,23?/m0/s1

Upstream product

• 14927-19-6 11β-hydroxy-2'-methyl-(5α,16β)-pregnano[17,16-d]oxazole-3,20-dione 
• 19864-81-4 2'-methyl-(16β)-pregna-1,4,9(11)-trieno[17,16-d]oxazole-3,20-dione 
• 16119-50-9 3β-hydroxy-2'-methyl-(5α,16β)-pregnano[17,16-d]oxazole-11,20-dione 20-semicarbazone 
• 13649-85-9 3β,11β-dihydroxy-2'-methyl-(5α,16β)-pregnano[17,16-d]oxazol-20-one semicarbazone 
• 13649-86-0 3β,11β-dihydroxy-2'-methyl-(5α,16β)-pregnano[17,16-d]oxazol-20-one 
• 19890-68-7 3β-acetoxy-2'-methyl-(5α,16β)-pregn-9(11)-eno[17,16-d]oxazol-20-one 
• 13649-87-1 3β-acetoxy-11β-hydroxy-2'-methyl-(5α,16β)-pregnano[17,16-d]oxazol-20-one 
• 22222-77-1 2'-methyl-(5α,16β)-pregn-9(11)-eno[17,16-d]oxazole-3,20-dione 
• 19890-69-8 3β-hydroxy-2'-methyl-(5α,16β)-pregn-9(11)-eno[17,16-d]oxazol-20-one 

Downstream Products

• 14484-47-0 deflazacort 
• 16119-56-5 21-acetoxy-2'-methyl-(16β)-pregna-1,4,9(11)-trieno[17,16-d]oxazole-3,20-dione 

Related news

Case ReportToxic epidermal necrolysis associated with DEFLAZACORT (cas 13649-88-2) therapy with nephrotic syndrome09/25/2019

Toxic epidermal necrolysis (TEN) is a drug-related fatal disease. Extensive necrosis of the epidermis can lead to serious complications. This report describes two cases of TEN, associated with deflazacort (DFZ), in two boys, aged 4 years and 14 years, with nephrotic syndrome (NS). The 14-year-ol...detailed

A comparative study of hydrocortisone versus DEFLAZACORT (cas 13649-88-2) in drug-resistant epilepsy of childhood09/24/2019

SummarySteroids are commonly used for the treatment of intractable epilepsy. Deflazacort has shown similar effects to prednisone, but with a less worrying adverse-effect profile. In this study, we first compared the efficacy, safety, and seizure relapse rate of deflazacort versus hydrocortisone ...detailed

Identification of plasma interleukins as biomarkers for DEFLAZACORT (cas 13649-88-2) and omega-3 based Duchenne muscular dystrophy therapy09/10/2019

Duchenne muscular dystrophy (DMD) is a progressive and fatal disease, characterized by the absence of dystrophin, muscle degeneration and cardiorespiratory failure. Creatine kinase is the classic marker to screen for DMD. However, other markers are needed to follow disease progression and to eva...detailed

Short communicationIsolation and structural characterization of novel photolytic degradation impurities of DEFLAZACORT (cas 13649-88-2) using Q-TOF, 2D-NMR and FTIR09/08/2019

Forced Degradation of Deflazacort drug substance in ultraviolet light condition resulted into a number of significant degradation products. Two of these degradation products were found to be unknown during the study and marked as DD-I and DD-II. Thus, the objective of this work is to investigate...detailed

Determination of the solubility, dissolution enthalpy and entropy of DEFLAZACORT (cas 13649-88-2) in different solvents09/06/2019

The solubility of Deflazacort in four solvents, acetone, ethyl acetate, ethanol and 2-propanol, was measured at temperatures ranging from 293.15 K to 348.15 K at atmospheric pressure using Laser Monitoring Technique. The solubility data were correlated by the modified Apelblat model. Then the di...detailed

Clinical ObservationsThe Impact of DEFLAZACORT (cas 13649-88-2) on Puberty in Duchenne Muscular Dystrophy09/05/2019

BackgroundThe routine use of glucocorticoids has increased the longevity of patients with Duchenne muscular dystrophy. Long-term steroid therapy may have adverse effects on endocrine function and could influence the onset of puberty.detailed